INS and Hypertension: At study entry and before starting pasireotide, the patient was affected by overweight, hypertension, treated with nebivolol (5 mg/die) and canrenone (100 mg/die), DM, treated with short-acting (32 IU/die) and long-acting insulin (15 IU/die), and mixed dyslipidemia, treated with diet.